NASDAQ:CTRV - ContraVir Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.27 -0.01 (-3.61 %)
(As of 03/21/2019 08:44 AM ET)
Previous Close$0.2750
Today's Range$0.2511 - $0.2749
52-Week Range$0.21 - $2.60
Volume178,449 shs
Average Volume395,721 shs
Market Capitalization$4.59 million
P/E RatioN/A
Dividend YieldN/A
Beta1.86
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection. The company was founded in 2013 and is headquartered in Edison, New Jersey.

Receive CTRV News and Ratings via Email

Sign-up to receive the latest news and ratings for CTRV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTRV
CUSIPN/A
Phone732-902-4000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.01 per share

Profitability

Net Income$-9,450,000.00

Miscellaneous

EmployeesN/A
Market Cap$4.59 million
Next Earnings DateN/A
OptionableNot Optionable

ContraVir Pharmaceuticals (NASDAQ:CTRV) Frequently Asked Questions

What is ContraVir Pharmaceuticals' stock symbol?

ContraVir Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTRV."

When did ContraVir Pharmaceuticals' stock split? How did ContraVir Pharmaceuticals' stock split work?

ContraVir Pharmaceuticals shares reverse split on the morning of Tuesday, May 29th 2018. The 1-8 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 28th 2018. An investor that had 100 shares of ContraVir Pharmaceuticals stock prior to the reverse split would have 13 shares after the split.

How were ContraVir Pharmaceuticals' earnings last quarter?

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) released its quarterly earnings results on Friday, May, 13th. The biopharmaceutical company reported ($1.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.80) by $0.68. View ContraVir Pharmaceuticals' Earnings History.

What is the consensus analysts' recommendation for ContraVir Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraVir Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ContraVir Pharmaceuticals.

Has ContraVir Pharmaceuticals been receiving favorable news coverage?

Media stories about CTRV stock have trended negative this week, according to InfoTrie. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ContraVir Pharmaceuticals earned a news impact score of -2.2 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the stock's share price in the near future.

Who are some of ContraVir Pharmaceuticals' key competitors?

What other stocks do shareholders of ContraVir Pharmaceuticals own?

Who are ContraVir Pharmaceuticals' key executives?

ContraVir Pharmaceuticals' management team includes the folowing people:
  • Dr. John Z. Sullivan-Bolyai, Part-Time Consultant & Member of Scientific Advisory Board (Age 70)
  • Dr. Robert T. Foster BSc (Pharm), Pharm.D., Ph.D., CEO, Chief Scientific Officer & Director (Age 60)
  • Mr. John T. Cavan, Chief Financial Officer (Age 60)
  • Sharen Pyatetskaya, Director of Investor Relations

Who are ContraVir Pharmaceuticals' major shareholders?

ContraVir Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Barclays PLC (1.08%). View Institutional Ownership Trends for ContraVir Pharmaceuticals.

Which major investors are buying ContraVir Pharmaceuticals stock?

CTRV stock was bought by a variety of institutional investors in the last quarter, including Barclays PLC. View Insider Buying and Selling for ContraVir Pharmaceuticals.

How do I buy shares of ContraVir Pharmaceuticals?

Shares of CTRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ContraVir Pharmaceuticals' stock price today?

One share of CTRV stock can currently be purchased for approximately $0.2670.

How big of a company is ContraVir Pharmaceuticals?

ContraVir Pharmaceuticals has a market capitalization of $4.59 million.

What is ContraVir Pharmaceuticals' official website?

The official website for ContraVir Pharmaceuticals is http://www.contravir.com.

How can I contact ContraVir Pharmaceuticals?

ContraVir Pharmaceuticals' mailing address is 399 THORNALL STREET FIRST FLOOR, EDISON NJ, 08837. The biopharmaceutical company can be reached via phone at 732-902-4000 or via email at [email protected]


MarketBeat Community Rating for ContraVir Pharmaceuticals (NASDAQ CTRV)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  174 (Vote Outperform)
Underperform Votes:  105 (Vote Underperform)
Total Votes:  279
MarketBeat's community ratings are surveys of what our community members think about ContraVir Pharmaceuticals and other stocks. Vote "Outperform" if you believe CTRV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTRV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel